Treatment with rilparencel stabilized kidney function as measured by the annual decline in patients' glomerular filtration rate (eGFR). The eGFR decline for folks randomized to receive two rilparencel injections, one in each kidney, was 78% slower than the placebo group. This suggests the treatment can dramatically lower patients' risk of progression to kidney failure and reduce their need for dialysis and transplantation. Dialysis isn't cheap, and monitoring transplants for rejection is another pricey acti ...